Targeting thapsigargin towards tumors

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Targeting thapsigargin towards tumors. / Christensen, Søren Brøgger; Doan, Thi Quynh Nhu; Paulsen, Eleonora Sandholdt; Sehgal, Pankaj; Møller, Jesper Vuust; Nissen, Poul; Denmeade, Samuel R.; Isaacs, John T.; Dionne, Craig A.

In: Steroids, Vol. 97, 2015, p. 2-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Christensen, SB, Doan, TQN, Paulsen, ES, Sehgal, P, Møller, JV, Nissen, P, Denmeade, SR, Isaacs, JT & Dionne, CA 2015, 'Targeting thapsigargin towards tumors', Steroids, vol. 97, pp. 2-7. https://doi.org/10.1016/j.steroids.2014.07.009

APA

Christensen, S. B., Doan, T. Q. N., Paulsen, E. S., Sehgal, P., Møller, J. V., Nissen, P., Denmeade, S. R., Isaacs, J. T., & Dionne, C. A. (2015). Targeting thapsigargin towards tumors. Steroids, 97, 2-7. https://doi.org/10.1016/j.steroids.2014.07.009

Vancouver

Christensen SB, Doan TQN, Paulsen ES, Sehgal P, Møller JV, Nissen P et al. Targeting thapsigargin towards tumors. Steroids. 2015;97:2-7. https://doi.org/10.1016/j.steroids.2014.07.009

Author

Christensen, Søren Brøgger ; Doan, Thi Quynh Nhu ; Paulsen, Eleonora Sandholdt ; Sehgal, Pankaj ; Møller, Jesper Vuust ; Nissen, Poul ; Denmeade, Samuel R. ; Isaacs, John T. ; Dionne, Craig A. / Targeting thapsigargin towards tumors. In: Steroids. 2015 ; Vol. 97. pp. 2-7.

Bibtex

@article{95a09b691bdd48d1a9db986959edee32,
title = "Targeting thapsigargin towards tumors",
abstract = "The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structureelucidated. By inhibiting the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) thapsigargin provokesapoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for eitherprostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created,which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug iscurrently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.",
author = "Christensen, {S{\o}ren Br{\o}gger} and Doan, {Thi Quynh Nhu} and Paulsen, {Eleonora Sandholdt} and Pankaj Sehgal and M{\o}ller, {Jesper Vuust} and Poul Nissen and Denmeade, {Samuel R.} and Isaacs, {John T.} and Dionne, {Craig A}",
year = "2015",
doi = "10.1016/j.steroids.2014.07.009",
language = "English",
volume = "97",
pages = "2--7",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Targeting thapsigargin towards tumors

AU - Christensen, Søren Brøgger

AU - Doan, Thi Quynh Nhu

AU - Paulsen, Eleonora Sandholdt

AU - Sehgal, Pankaj

AU - Møller, Jesper Vuust

AU - Nissen, Poul

AU - Denmeade, Samuel R.

AU - Isaacs, John T.

AU - Dionne, Craig A

PY - 2015

Y1 - 2015

N2 - The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structureelucidated. By inhibiting the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) thapsigargin provokesapoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for eitherprostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created,which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug iscurrently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.

AB - The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structureelucidated. By inhibiting the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) thapsigargin provokesapoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for eitherprostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created,which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug iscurrently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.

U2 - 10.1016/j.steroids.2014.07.009

DO - 10.1016/j.steroids.2014.07.009

M3 - Journal article

C2 - 25065587

VL - 97

SP - 2

EP - 7

JO - Steroids

JF - Steroids

SN - 0039-128X

ER -

ID: 162907761